Award
National Cancer Institute 5R44CA265510-05
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL)
Recipient
Boston Immune Technologies and Therapeutics, Inc.
Award Amount
$2,409,283.00
Ceiling
$2,409,283.00
Awarded
July 11, 2025
Identifier
5R44CA265510-05
The award funds a clinical trial to develop and validate BITR2101, an antibody antagonist targeting TNFR2, for treating Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma, aiming to improve cancer therapy outcomes.
Description
This project involves developing and validating an antibody therapeutic targeting TNFR2 for cancer treatment, with clinical validation in NHL/CTCL and potential expansion to other cancers. BITT is developing BITR2101, an antagonist antibody targeting TNFR2, a receptor highly expressed in cancer tissue and immune suppressive cells, mediating pro-survival signaling. The project aims to accelerate clinical validation of BITR2101 in NHL/CTCL, demonstrating its value in cancer therapy and expanding its application to other malignancies.